Stay updated on Avapritinib vs Placebo in Indolent Systemic Mastocytosis Clinical Trial
Sign up to get notified when there's something new on the Avapritinib vs Placebo in Indolent Systemic Mastocytosis Clinical Trial page.

Latest updates to the Avapritinib vs Placebo in Indolent Systemic Mastocytosis Clinical Trial page
- Check4 days agoChange DetectedRevision tag updated from v3.5.3 to v3.5.4 on the page. This represents a minor platform update with no evident changes to the study details or page layout in the provided context.SummaryDifference0.0%

- Check11 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedThe page’s footer “Revision” label was updated from v3.5.2 to v3.5.3, reflecting a site/version update rather than a change to the study record.SummaryDifference0.0%

- Check33 days agoChange DetectedRevision updated to v3.5.2, replacing the previous v3.5.0 revision.SummaryDifference0.0%

- Check61 days agoChange DetectedRevision: v3.5.0 was added and Revision: v3.4.3 was removed in the site’s release notes.SummaryDifference0.0%

- Check76 days agoChange DetectedRevision label updated from v3.4.2 to v3.4.3. This is a metadata/display change and does not affect study information or functionality.SummaryDifference0.0%

- Check90 days agoChange DetectedAdded a new publication citation: Avapritinib improves cutaneous involvement in indolent systemic mastocytosis from the PIONEER study (J Am Acad Dermatol, online ahead of print).SummaryDifference0.0%

Stay in the know with updates to Avapritinib vs Placebo in Indolent Systemic Mastocytosis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Avapritinib vs Placebo in Indolent Systemic Mastocytosis Clinical Trial page.